ASP9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3. ASP9521 inhibited conversion of androstenedione (AD) into testosterone (T) by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L). ASP9521 showed >100-fold selectivity for AKR1C3 over the isoform AKR1C2. In LNCaP-AKR1C3 cells, ASP9521 suppressed AD-dependent PSA production and cell proliferation.
In vivo, single oral administration of ASP-9521 (3 mg/kg) inhibits AD-induced intratumoural T production in CWR22R xenografts, and this inhibitory effect is maintained for 24 h. After oral administration, ASP-9521 is rapidly eliminated from plasma, while its intratumoural concentration remained high. The bioavailability of ASP9521 after oral administration (1 mg/kg) is 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.
| Cell Experiment | |
|---|---|
| Cell lines | LNCaP-AKR1C3 cells stably expressing human AKR1C3 |
| Preparation method | LNCaP-AKR1C3 cells stably expressing human AKR1C3 are seeded in 96-well plates at 10000 cells/100 μL/well in RPMI-1640 medium supplemented with heat-inactivated charcoal-dextran-stripped FBS (1 % for the PSA expression assay and T measurement and 5 % for the cell proliferation assay). After 24 h incubation, AD is added to each well with or without ASP-9521 (0.3-100 nM). The cell culture media are collected 24 h after administration of AD to measure T concentration and 6 days after administration of AD to measure cell proliferation using Cell-Titer Glo assay. |
| Concentrations | 0.3-100 nM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Mice carrying HEK293 or HEK293-AKR1C3 tumours |
| Formulation | 0.5 % methyl cellulose |
| Dosages | 3 mg/kg |
| Administration | single oral |
| Molecular Weight | 330.42 |
| Formula | C19H26N2O3 |
| CAS Number | 1126084-37-4 |
| Solubility (25°C) | DMSO: ≥ 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Hydroxysteroid dehydrogenase Products |
|---|
| ARO-HSD
ARO-HSD is an siRNA and also an inhibitor of 17β-HSD13 that can be used in studies related to non-alcoholic steatohepatitis (NASH). |
| ALN-HSD
ALN-HSD is an siRNA and also an inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17β-HSD13), which can be used in studies related to non-alcoholic steatohepatitis (NASH). |
| ABT-384
ABT-384 is a potent, selective 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. ABT-384 exhibits high affinity (Ki 0.1-2.7 nM) against rodent, monkey, and human 11β-HSD1. ABT-384 blocks regeneration of active cortisol. ABT-384 can be used for the research of Alzheimer’s disease (AD). |
| SCH-451659
SCH-451659 is an inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) for cancer research. |
| BI‑3231
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
